#BEGIN_DRUGCARD DB01672

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
303-38-8

# ChEBI_ID:
18026

# Chemical_Formula:
C7H6O4

# Chemical_IUPAC_Name:
2,3-dihydroxybenzoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Iron Chelating Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.20

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2,3-Dihydroxy-Benzoic Acid

# HET_ID:
DBH

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C7H6O4/c8-5-3-1-2-4(6(5)9)7(10)11/h1-3,8-9H,(H,10,11)

# InChI_Key:
InChIKey=GLDQAMYCGOIJDV-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00196

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1672

# Mechanism_Of_Action:
Not Available

# Melting_Point:
204 °C

# Molecular_Weight_Avg:
154.1201

# Molecular_Weight_Mono:
154.02660868

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1MDB

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.42

# Predicted_LogS:
-1.4

# Predicted_Water_Solubility:
6.88e+00 g/l

# Primary_Accession_No:
DB01672

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
19

# PubChem_Substance_ID:
46504857

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01121

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)C1=CC=CC(O)=C1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:23 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
2.91 (at 25 °C)

# Drug_Target_1_Cellular_Location:
Cell membrane
multi-pass membrane protein (Potential)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U26444

# Drug_Target_1_GenBank_ID_Protein:
837332

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
dhbE

# Drug_Target_1_Gene_Sequence:
>1620 bp
ATGCTGAAAGGATTTACGCCTTGGCCTGATGAGTTAGCTGAGACCTATCGAAAGAACGGC
TGCTGGGCCGGTGAGACGTTTGGAGATTTGTTAAGGGACCGGGCAGCCAAATATGGTGAT
CGCATTGCCATTACATGCGGAAACACCCATTGGAGCTATCGAGAGCTTGACACAAGGGCT
GATCGCCTGGCTGCCGGATTTCAAAAGCTCGGCATTCAACAGATGGATCGTGTTGTGGTG
CAGTTGCCAAATATCAAAGAGTTTTTTGAAGTCATTTTCGCGCTTTTCCGTCTGGGGGCG
CTTCCAGTCTTCGCACTGCCTTCTCATCGAAGCAGTGAAATTACATATTTTTGCGAGTTT
GCTGAAGCGGCTGCATATATCATTCCCGACGCTTATTCCGGTTTTGACTACCGTTCGCTT
GCCAGACAGGTTCAAAGCAAGCTGCCGACTTTGAAAAACATCATTGTCGCAGGTGAGGCA
GAGGAATTTTTACCGCTGGAGGATTTGCATGCAGAACCTGTAAAACTGCCTGAAGTCAAA
TCATCGGATGTGGCGTTCCTCCAGCTTTCTGGCGGGAGCACCGGGCTATCGAAACTGATT
CCGAGGACCCACGATGACTACATATACAGCCTGAAGCGGAGTGTGGAGGTCTGCTGGCTC
GACCACAGCACGGTGTACTTGGCCGCGCTGCCGATGGCACACAATTATCCGCTGAGCTCA
CCCGGCGTTCTCGGCGTATTATACGCTGGAGGAAGAGTGGTATTATCTCCTTCTCCAAGT
CCAGATGACGCATTTCCTTTAATTGAACGGGAAAAGGTCACGATAACCGCTCTTGTTCCG
CCTCTTGCGATGGTATGGATGGATGCGGCATCCTCACGCCGTGATGATTTATCCAGCCTT
CAAGTGCTGCAGGTCGGCGGTGCCAAGTTTAGTGCTGAAGCCGCGCGCAGGGTAAAAGCT
GTTTTCGGCTGCACGCTGCAGCAGGTGTTCGGAATGGCAGAGGGTCTCGTCAATTATACG
AGATTGGATGATCCTGAGGAGATCATTGTCAACACCCAAGGAAAACCGATGTCTCCATAT
GATGAAATGCGTGTTTGGGATGATCATGATCGCGACGTAAAACCTGGTGAAACAGGCCAT
CTGCTGACGCGGGGGCCGTATACAATTCGAGGTTACTATAAGGCAGAAGAGCATAACGCC
GCTTCATTTACTGAGGACGGTTTTTACCGTACGGGTGATATCGTCAGGCTGACACGAGAC
GGCTATATTGTCGTTGAAGGCCGGGCGAAGGATCAAATTAACCGTGGAGGAGAAAAGGTT
GCGGCTGAAGAGGTAGAAAATCATCTGCTGGCGCATCCGGCTGTCCATGATGCGGCAATG
GTCTCCATGCCTGATCAATTTCTTGGCGAAAGATCTTGTGTGTTCATTATTCCCCGGGAT
GAAGCCCCAAAAGCCGCAGAGCTTAAAGCATTTTTGAGAGAGCGCGGACTGGCGGCATAT
AAAATCCCTGATCGAGTTGAATTTGTCGAATCCTTCCCGCAGACAGGAGTAGGAAAAGTC
AGCAAAAAAGCGCTCCGTGAAGCCATTTCCGAGAAGCTTCTTGCAGGATTTAAAAAATAA

# Drug_Target_1_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_1_General_References:
12221282	May JJ, Kessler N, Marahiel MA, Stubbs MT: Crystal structure of DhbE, an archetype for aryl acid activating domains of modular nonribosomal peptide synthetases. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12120-5. Epub 2002 Sep 9.
8224884	Adams R, Schumann W: Cloning and mapping of the Bacillus subtilis locus homologous to Escherichia coli ent genes. Gene. 1993 Oct 29;133(1):119-21.
8921902	Rowland BM, Grossman TH, Osburne MS, Taber HW: Sequence and genetic organization of a Bacillus subtilis operon encoding 2,3-dihydroxybenzoate biosynthetic enzymes. Gene. 1996 Oct 31;178(1-2):119-23.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2271

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
59929

# Drug_Target_1_Name:
2,3-dihydroxybenzoate-AMP ligase

# Drug_Target_1_Number_of_Residues:
539

# Drug_Target_1_PDB_ID:
1MDF

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00501	AMP-binding

# Drug_Target_1_Protein_Sequence:
>2,3-dihydroxybenzoate-AMP ligase
MLKGFTPWPDELAETYRKNGCWAGETFGDLLRDRAAKYGDRIAITCGNTHWSYRELDTRA
DRLAAGFQKLGIQQMDRVVVQLPNIKEFFEVIFALFRLGALPVFALPSHRSSEITYFCEF
AEAAAYIIPDAYSGFDYRSLARQVQSKLPTLKNIIVAGEAEEFLPLEDLHAEPVKLPEVK
SSDVAFLQLSGGSTGLSKLIPRTHDDYIYSLKRSVEVCWLDHSTVYLAALPMAHNYPLSS
PGVLGVLYAGGRVVLSPSPSPDDAFPLIEREKVTITALVPPLAMVWMDAASSRRDDLSSL
QVLQVGGAKFSAEAARRVKAVFGCTLQQVFGMAEGLVNYTRLDDPEEIIVNTQGKPMSPY
DEMRVWDDHDRDVKPGETGHLLTRGPYTIRGYYKAEEHNAASFTEDGFYRTGDIVRLTRD
GYIVVEGRAKDQINRGGEKVAAEEVENHLLAHPAVHDAAMVSMPDQFLGERSCVFIIPRD
EAPKAAELKAFLRERGLAAYKIPDRVEFVESFPQTGVGKVSKKALREAISEKLLAGFKK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Activation of the carboxylate group of 2,3-dihydroxy- benzoate (DHB), via ATP-dependent PPi exchange reactions, to the acyladenylate

# Drug_Target_1_SwissProt_ID:
P40871

# Drug_Target_1_SwissProt_Name:
DHBE_BACSU

# Drug_Target_1_Synonyms:
Dihydroxybenzoic acid- activating enzyme
EC 6.3.2.-

# Drug_Target_1_Theoretical_pI:
5.98

# Drug_Target_1_Transmembrane_Regions:
91-107
273-290

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
LCN2

# Drug_Target_2_GenBank_ID_Gene:
X83006

# Drug_Target_2_GenBank_ID_Protein:
929657

# Drug_Target_2_GeneCard_ID:
LCN2

# Drug_Target_2_Gene_Name:
LCN2

# Drug_Target_2_Gene_Sequence:
>597 bp
ATGCCCCTAGGTCTCCTGTGGCTGGGCCTAGCCCTGTTGGGGGCTCTGCATGCCCAGGCC
CAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAG
AACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCA
ATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAA
GACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATC
AGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTAC
CCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATG
GTGTTCTTTAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA
ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGC
CTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCTGA

# Drug_Target_2_General_Function:
Involved in lipophilic molecule transport

# Drug_Target_2_General_References:
10339412	Coles M, Diercks T, Muehlenweg B, Bartsch S, Zolzer V, Tschesche H, Kessler H: The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol. 1999 May 28;289(1):139-57.
10684642	Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000 Feb 29;39(8):1935-41.
1281792	Triebel S, Blaser J, Reinke H, Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992 Dec 21;314(3):386-8.
7683678	Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993 May 15;268(14):10425-32.
7835423	Bartsch S, Tschesche H: Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett. 1995 Jan 9;357(3):255-9.
8060329	Bundgaard JR, Sengelov H, Borregaard N, Kjeldsen L: Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1468-75.

# Drug_Target_2_HGNC_ID:
HGNC:6526

# Drug_Target_2_HPRD_ID:
02551

# Drug_Target_2_ID:
1782

# Drug_Target_2_Locus:
9q34

# Drug_Target_2_Molecular_Weight:
22588

# Drug_Target_2_Name:
Neutrophil gelatinase-associated lipocalin

# Drug_Target_2_Number_of_Residues:
198

# Drug_Target_2_PDB_ID:
1NGL

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00061	Lipocalin

# Drug_Target_2_Protein_Sequence:
>Neutrophil gelatinase-associated lipocalin precursor
MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNA
ILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSY
PGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLG
LPENHIVFPVPIDQCIDG

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-20

# Drug_Target_2_Specific_Function:
Transport of small lipophilic substances (Potential)

# Drug_Target_2_SwissProt_ID:
P80188

# Drug_Target_2_SwissProt_Name:
NGAL_HUMAN

# Drug_Target_2_Synonyms:
25 kDa alpha-2-microglobulin-related subunit of MMP-9
Lipocalin-2
NGAL
Neutrophil gelatinase-associated lipocalin precursor
Oncogene 24p3
p25

# Drug_Target_2_Theoretical_pI:
9.24

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01672
